Last updated on March 2019

A Study of ASP2215 (Gilteritinib) by Itself ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy


Brief description of study

This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. AML is a type of cancer. It is when bone marrow makes white blood cells that are not normal. These are called leukemia cells. Some patients with AML have a mutation, or change, in the FLT3 gene. This gene helps leukemia cells make a protein called FLT3. This protein causes the leukemia cells to grow faster.

For patients with AML who cannot receive standard chemotherapy, azacitidine (also known as Vidaza) is a current standard of care treatment option in the United States. This clinical study is testing an experimental medicine called ASP2215, also known as gilteritinib. Gilteritinib works by stopping the leukemia cells from making the FLT3 protein. This can help stop the leukemia cells from growing faster.

This study will compare two different treatments. Patients are assigned to one of these two groups by chance: a medicine called azacitidine, also known as Vidaza, or an experimental medicine gilteritinib in combination with azacitidine. There is a twice as much chance to receive both medicines combined than azacitidine alone. The clinical study may help show which treatment helps patients live longer.

Detailed Study Description

Patients considered an adult according to local regulation at the time of obtaining informed consent may participate in the study.

Safety Cohort Prior to initiation of the randomized trial, 8 to 12 patients will be enrolled to evaluate the safety and tolerability of ASP2215 given with azacitidine therapy in the study population.

Randomized Trial Approximately 323 patients will be randomized in a 2:1 ratio to receive ASP2215 plus azacitidine (Arm AC) or azacitidine only (Arm C).

Earlier protocol versions included a 1:1:1 randomization ratio to receive Arm A: ASP2215, Arm AC: ASP2215 + azacitidine or Arm C: azacitidine. Randomization to Arm A was removed in the current protocol version. Patients previously randomized to Arm A should continue following treatment and assessments as outlined in the protocol.

Patients will enter the screening period up to 14 days prior to the start of treatment. Patients will be administered treatment over 28-day cycles.

Clinical Study Identifier: NCT02752035

Contact Investigators or Research Sites near you

Start Over

Astellas Pharma Global Development

Site AU61012
Camperdown, Australia
  Connect »

Astellas Pharma Global Development

Site AU61004
Liverpool, Australia
  Connect »

Astellas Pharma Global Development

Site AU61008
Adelaide, Australia
  Connect »

Astellas Pharma Global Development

Site AU61007
Geelong, Australia
  Connect »

Astellas Pharma Global Development

Site BE32003
Bruxelles, Belgium
  Connect »

Astellas Pharma Global Development

Site CA15009
Edmonton, AB Canada
  Connect »

Astellas Pharma Global Development

Site CA15004
Halifax, NS Canada
  Connect »

Astellas Pharma Global Development

Site CA15002
Toronto, ON Canada
  Connect »

Astellas Pharma Global Development

Site CA15006
Montreal, QC Canada
  Connect »

Astellas Pharma Global Development

Site FR33019
Montpellier Cedex 5, France
  Connect »

Astellas Pharma Global Development

Site FR33001
Nantes cedex 01, France
  Connect »

Astellas Pharma Global Development

Site FR33014
Vandoeuvre les Nancy, France
  Connect »

Astellas Pharma Global Development

Site FR33013
Pierre-Benite, France
  Connect »

Astellas Pharma Global Development

Site FR33007
Le Chesnay Cedex, France
  Connect »

Astellas Pharma Global Development

Site FR33004
Lille cedex, France
  Connect »

Astellas Pharma Global Development

Site DE49002
Tuebingen, Germany
  Connect »

Astellas Pharma Global Development

Site DE49012
Braunschweig, Germany
  Connect »

Astellas Pharma Global Development

Site DE49004
Hannover, Germany
  Connect »

Astellas Pharma Global Development

Site DE49009
Halle (Saale), Germany
  Connect »

Astellas Pharma Global Development

Site DE49013
Heilbronn, Germany
  Connect »

Astellas Pharma Global Development

Site DE49011
Stuttgart, Germany
  Connect »

Astellas Pharma Global Development

Site JP81014
Shinagawa-ku, Japan
  Connect »

Astellas Pharma Global Development

Site KR82003
Namdong, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site KR82013
Seoul, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site KR82008
Seoul, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site KR82006
Seoul, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site KR82002
Seoul, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site KR82001
Ulsan, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site KR82014
Busan, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site KR82012
Seoul, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site ES34007
Palma de Mallorca, Spain
  Connect »

Astellas Pharma Global Development

Site TW88604
Kaohsiung, Taiwan
  Connect »

Astellas Pharma Global Development

Site GB44004
London, United Kingdom
  Connect »

Astellas Pharma Global Development

University of Southern California
Los Angeles, CA United States
  Connect »

Astellas Pharma Global Development

UCLA David Geffen School of Medicine
Los Angeles, CA United States
  Connect »

Astellas Pharma Global Development

University of California, Irvine Medical Center
Orange, CA United States
  Connect »

Astellas Pharma Global Development

Yale-New Haven Hospital (YNHH) - Smilow Cancer Hospital
New Haven, CT United States
  Connect »

Astellas Pharma Global Development

University of Florida
Gainesville, FL United States
  Connect »

Astellas Pharma Global Development

Augusta University - Georgia Cancer Center
Augusta, GA United States
  Connect »

Astellas Pharma Global Development

Robert H. Lurie Comprehensive Cancer Center
Chicago, IL United States
  Connect »

Astellas Pharma Global Development

Rush University Medical Center
Chicago, IL United States
  Connect »

Astellas Pharma Global Development

University of Chicago
Chicago, IL United States
  Connect »

Astellas Pharma Global Development

Loyola University Medical Center
Maywood, IL United States
  Connect »

Astellas Pharma Global Development

Norton Cancer Institute
Louisville, KY United States
  Connect »

Astellas Pharma Global Development

Tulane University Health Sciences Center
New Orleans, LA United States
  Connect »

Astellas Pharma Global Development

Eastern Maine Medical Center - CancerCare of Maine
Brewer, ME United States
  Connect »

Astellas Pharma Global Development

Hackensack University Medical Center - John Theurer Cancer Center
Hackensack, NJ United States
  Connect »

Astellas Pharma Global Development

Hematology-Oncology Associates of Northern NJ
Morristown, NJ United States
  Connect »

Astellas Pharma Global Development

Roswell Park Cancer Institute
Buffalo, NY United States
  Connect »

Astellas Pharma Global Development

Mount Sinai Downtown Union Square
New York, NY United States
  Connect »

Astellas Pharma Global Development

Manhattan Hematology Oncology Associates, P.C.
New York, NY United States
  Connect »

Astellas Pharma Global Development

Weill Cornell Medical College-New York Presbyterian Hospital
New York, NY United States
  Connect »

Astellas Pharma Global Development

SUNY Upstate Medical University
Syracuse, NY United States
  Connect »

Astellas Pharma Global Development

University of Oklahoma Health Sciences Center
Oklahoma City, OK United States
  Connect »

Astellas Pharma Global Development

Penn State Hershey Cancer Institute
Hershey, PA United States
  Connect »

Astellas Pharma Global Development

GHS Cancer Institute
Greenville, SC United States
  Connect »

Astellas Pharma Global Development

Baylor Research Institute
Dallas, TX United States
  Connect »

Astellas Pharma Global Development

The University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »

Astellas Pharma Global Development

LDS Hospital
Salt Lake City, UT United States
  Connect »

Astellas Pharma Global Development

Swedish Cancer Institute / Swedish Health Services
Seattle, WA United States
  Connect »

Astellas Pharma Global Development

Site BE32008
Montigny-le-Tilleul, Belgium
  Connect »

Astellas Pharma Global Development

Site FR33003
Nimes Cedex 09, France
  Connect »

Astellas Pharma Global Development

Site DE49005
Frankfurt, Germany
  Connect »

Astellas Pharma Global Development

Site JP81012
Sendai-shi, Japan
  Connect »

Astellas Pharma Global Development

Site JP81029
Shibuya-ku, Japan
  Connect »

Astellas Pharma Global Development

Site JP81007
Nagoya-shi, Japan
  Connect »

Astellas Pharma Global Development

Site JP81030
Osaka City, Japan
  Connect »

Astellas Pharma Global Development

Site KR82010
Hwasun-gun, Korea, Republic of
  Connect »

Astellas Pharma Global Development

Site ES34012
Valladolid, Spain
  Connect »

Astellas Pharma Global Development

Site TW88605
Kwei Shan Hsiang, Taiwan
  Connect »

Astellas Pharma Global Development

Memorial Sloan-Kettering Cancer Center
New York, NY United States
  Connect »

Astellas Pharma Global Development

Orlando Health Inc - Clinic
Orlando, FL United States
  Connect »

Astellas Pharma Global Development

Medical City Dallas Hospital
Dallas, TX United States
  Connect »

Astellas Pharma Global Development

Site IT39011
San Giovanni Rotondo, Italy
  Connect »

Astellas Pharma Global Development

Indiana Blood Marrow Transplantation
Indianapolis, IN United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.